GRB7

Across TCGA pan-cancer cohorts, GRB7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRB7 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GRB7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GRB7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where GRB7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.728	0.926	.016	5	view →
CCRCC	DFS	Median	All	1.000	0.729	.017	5	view →
HNSC	OS	Median	IV	0.943	0.740	.023	5	view →
OV	DFS	Median	All	0.861	1.000	.030	4	view →
LUAD	OS	Median	III,IV	0.765	0.337	.029	2	view →
LSCC	DFS	Median	III,IV	0.650	0.916	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRB7–PDAC (OS)

Open the PDAC breakdown →